Novanta (NOVT) Aktievy
Novanta Inc. och dess dotterbolag tillhandahåller precisionsmedicin, precisionstillverkning, medicinska lösningar, robot- och automationslösningar samt lösningar för avancerad kirurgi i USA och internationellt. Mer information
| Snöflinga Score | |
|---|---|
| Värdering | 0/6 |
| Framtida tillväxt | 3/6 |
| Tidigare resultat | 1/6 |
| Finansiell hälsa | 6/6 |
| Utdelningar | 0/6 |
NOVT Community Fair Values
Create NarrativeSee what 9 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Novanta Inc. Konkurrenter
Prishistorik och prestanda
| Historiska aktiekurser | |
|---|---|
| Aktuell aktiekurs | US$127.87 |
| 52 veckors högsta | US$149.95 |
| 52 veckors lägsta | US$98.27 |
| Beta | 1.65 |
| 1 månads förändring | 8.03% |
| 3 månaders förändring | -4.96% |
| 1 års förändring | 4.83% |
| 3 års förändring | -21.26% |
| 5 års förändring | -0.79% |
| Förändring sedan börsintroduktionen | 702.31% |
Senaste nyheter och uppdateringar
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.Recent updates
NOVT: Future Earnings Power Will Rely On Executing Stronger Margins
Narrative update on Novanta The consensus analyst price target for Novanta has been raised by $12 to $150. Analysts cite updated models after Q4 results that indicate potential for stronger sales and margin performance.NOVT: Future Earnings Power Will Rely On Accelerating Sales And Margins
Analysts have trimmed their fair value estimate for Novanta from $160 to $157, reflecting a slightly higher discount rate and a modestly lower future P/E assumption, while still pointing to expectations for improving sales and margins after recent model updates. Analyst Commentary Bullish Takeaways Bullish analysts see room for the shares to move toward their updated fair value range, supported by model revisions that assume improving sales trends and margin recovery after recent results.NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their price target on Novanta to $150 from $138, citing updated Q4 models that suggest the company may be positioned for faster sales growth and margin expansion. Analyst Commentary Bullish Takeaways Bullish analysts point to the raised price target to $150 as a sign that updated Q4 assumptions support a higher valuation range for the shares.NOVT: Future Earnings Power Will Rely On Accelerating Margins
Analysts have lifted their fair value estimate for Novanta to $160 from $154, supported by updated models that reflect expectations for accelerating sales and margins following recent Q4 results and a higher Street price target of $150 from $138. Analyst Commentary Recent commentary points to a more constructive view on Novanta following its Q4 results, with updated models feeding into a higher fair value framework and a Street price target of $150.NOVT: Stable Outlook Will Rely On Steady Margins And Earnings Multiple
Narrative Update: Novanta Analyst Price Target The analyst price target for Novanta is unchanged at $154, as analysts keep their assumptions for fair value, discount rate, revenue growth, profit margin and future P/E essentially steady. Valuation Changes Fair Value: $154.00 remains effectively unchanged compared with the prior estimate of $154.NOVT: Equity Units Offering Will Support Balance Sheet And Future Deals
Analysts have nudged their price target on Novanta slightly higher to reflect modest tweaks to the discount rate, revenue growth, profit margin, and future P/E assumptions, framing the move as fine tuning rather than a major reset in expectations. What's in the News Novanta plans to look for acquisitions and investments, signaling an interest in adding to its portfolio of businesses (Key Developments).NOVT: Equity Units And Share Repurchases Will Support Balance Sheet And Future Deals
Analysts now keep their price target for Novanta effectively unchanged at about $154.00. They point to steady assumptions around discount rate, revenue growth, profit margin and future P/E as the key drivers of their view.NOVT: Equity Units Offering Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their fair value estimate for Novanta at approximately $154. They cite only marginal adjustments to the discount rate, long term revenue growth, profit margin assumptions, and future P/E, which do not materially change their overall outlook.NOVT: New Equity Raise Will Strengthen Balance Sheet And Support Future Deals
Analysts have maintained their price target for Novanta at approximately $154 per share. This reflects a steady outlook, as incremental adjustments to discount rate assumptions and long term growth and profitability estimates are viewed as too minor to warrant a change in fair value.NOVT: Expanded Equity Offering And Buybacks Will Drive Long Term Shareholder Value
Analysts have nudged their price target for Novanta slightly higher to align with its updated fair value of $154.00, reflecting modestly stronger confidence in the company’s steady growth and margin profile. What's in the News Novanta completed a $550 million composite tangible equity units offering, issuing 11 million units priced at $50 each, with a $1.375 discount per unit (Key Developments).NOVT: Expanded Buyback Authorization Will Increase Shareholder Value Going Forward
Narrative Update on Novanta: Analyst Price Target Change Analysts have maintained Novanta's fair value estimate at $154. They cited improved profitability metrics, which offset slight adjustments in the discount rate and growth projections.NOVT: Equity Buyback Expansion And Profit Margin Gains Will Drive Upside
Analysts have raised their fair value estimate for Novanta from $141.50 to $154.00 per share, citing expectations for stronger future revenue growth and improved profit margins, even though the discount rate is slightly higher. What's in the News Novanta Inc.Novanta Inc. (NASDAQ:NOVT) Looks Just Right With A 30% Price Jump
Oct 28
Is Now The Time To Look At Buying Novanta Inc. (NASDAQ:NOVT)?
Oct 07Novanta: The Solution To Elevated Expectations Is Lower Prices
Sep 29Novanta's (NASDAQ:NOVT) Returns Have Hit A Wall
Sep 13Robotics And Healthcare Demand Will Expand Market Opportunities
Novanta’s fair value outlook remains unchanged, as both the discount rate and future P/E shifted only marginally, leaving the consensus analyst price target steady at $141.50. What's in the News Novanta projects third quarter 2025 GAAP revenue of $244 million to $247 million and full year 2025 GAAP revenue of $970 million to $985 million.Novanta Inc.'s (NASDAQ:NOVT) Share Price Matching Investor Opinion
Aug 29Are Novanta Inc. (NASDAQ:NOVT) Investors Paying Above The Intrinsic Value?
Jun 16Returns At Novanta (NASDAQ:NOVT) Appear To Be Weighed Down
May 20Here's Why Novanta (NASDAQ:NOVT) Can Manage Its Debt Responsibly
May 03Should You Think About Buying Novanta Inc. (NASDAQ:NOVT) Now?
Apr 19Novanta: A Trusted Yet Premium Technology Partner
Apr 06Novanta Inc.'s (NASDAQ:NOVT) Stock Retreats 27% But Earnings Haven't Escaped The Attention Of Investors
Apr 05There May Be Some Bright Spots In Novanta's (NASDAQ:NOVT) Earnings
Mar 05Novanta (NASDAQ:NOVT) Has Some Way To Go To Become A Multi-Bagger
Feb 09Is Novanta (NASDAQ:NOVT) A Risky Investment?
Jan 24Should You Investigate Novanta Inc. (NASDAQ:NOVT) At US$151?
Jan 07Novanta: Delayed Recovery And Prolonged Struggles Ahead, Downgrade To Sell
Jan 01Novanta Inc.'s (NASDAQ:NOVT) Business Is Yet to Catch Up With Its Share Price
Dec 21Novanta (NASDAQ:NOVT) May Have Issues Allocating Its Capital
Oct 15What You Can Learn From Novanta Inc.'s (NASDAQ:NOVT) P/S
Sep 12Novanta Inc.: Overpriced In A Weak Demand Market. Here's Why It's A Hold
Sep 02
Innovative Medical Devices And Tactical Acquisitions Poised To Accelerate Company Growth
Focusing on medical devices with new products might significantly boost future revenue through innovation, aiming for notable revenue from new launches by 2025.Is It Too Late To Consider Buying Novanta Inc. (NASDAQ:NOVT)?
Aug 24Novanta Inc.'s (NASDAQ:NOVT) Intrinsic Value Is Potentially 21% Below Its Share Price
Aug 02Novanta (NASDAQ:NOVT) Might Be Having Difficulty Using Its Capital Effectively
Jun 22Does Novanta (NASDAQ:NOVT) Have A Healthy Balance Sheet?
May 30Investors Still Waiting For A Pull Back In Novanta Inc. (NASDAQ:NOVT)
May 08Aktieägarnas avkastning
| NOVT | US Electronic | US Marknad | |
|---|---|---|---|
| 7D | -4.6% | -2.9% | 0.8% |
| 1Y | 4.8% | 97.4% | 27.7% |
Avkastning vs industri: NOVT presterade sämre än US Electronic branschen som gav 97.4 % under det senaste året.
Avkastning vs Marknaden: NOVT presterade sämre än US marknaden som gav 27.7 % under det senaste året.
Prisvolatilitet
| NOVT volatility | |
|---|---|
| NOVT Average Weekly Movement | 6.3% |
| Electronic Industry Average Movement | 9.1% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
Stabil aktiekurs: NOVT har inte haft någon betydande prisvolatilitet under de senaste 3 månaderna jämfört med marknaden för US.
Volatilitet över tid: NOVT s veckovolatilitet ( 6% ) har varit stabil under det senaste året.
Om företaget
| Grundad | Anställda | VD OCH KONCERNCHEF | Webbplats |
|---|---|---|---|
| 1968 | 3,000 | Matthijs Glastra | www.novanta.com |
Novanta Inc. och dess dotterbolag tillhandahåller precisionsmedicin, precisionstillverkning, medicinska lösningar, robotik- och automationslösningar samt avancerade kirurgilösningar i USA och internationellt. Bolaget är verksamt inom segmenten Automation Enabling Technologies och Medical Solutions. Segmentet Precision Medicine and Manufacturing designar, tillverkar och marknadsför lösningar för styrning och skanning av laserstrålar, laserkällor, robot- och precisionsrörelser, verktyg för robotar i slutet av armar samt lagerspindlar.
Novanta Inc. Sammanfattning av grunderna
| NOVT grundläggande statistik | |
|---|---|
| Börsvärde | US$4.61b |
| Vinst(TTM) | US$53.83m |
| Intäkter(TTM) | US$980.60m |
84.6x
P/E-förhållande4.6x
P/S-förhållandeÄr NOVT övervärderat?
Se Verkligt värde och värderingsanalysResultat & intäkter
| NOVT resultaträkning (TTM) | |
|---|---|
| Intäkter | US$980.60m |
| Kostnad för intäkter | US$545.32m |
| Bruttovinst | US$435.28m |
| Övriga kostnader | US$381.46m |
| Intäkter | US$53.83m |
Senast redovisade vinst
Dec 31, 2025
Nästa vinstdatum
May 11, 2026
| Vinst per aktie (EPS) | 1.51 |
| Bruttomarginal | 44.39% |
| Nettovinstmarginal | 5.49% |
| Skuld/egenkapitalförhållande | 19.1% |
Hur har NOVT utvecklats på lång sikt?
Se historisk utveckling och jämförelseFöretagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/01 10:00 |
| Aktiekurs vid dagens slut | 2026/05/01 00:00 |
| Intäkter | 2025/12/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
Novanta Inc. bevakas av 8 analytiker. 3 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Robert Mason | Baird |
| Quinn Fredrickson | Baird |
| Andrew Buscaglia | Berenberg |